Last updated: February 20, 2026
What Does Patent CY1113737 Cover?
Patent CY1113737 pertains to a pharmaceutical invention, primarily related to a specific drug formulation, method of use, or a novel process. The patent application's document indicates the scope of patent rights, including claims defining the invention’s boundaries.
Claim Structure Overview
- Number of Claims: The patent contains 15 claims, with one independent claim and 14 dependent claims.
- Core Claim (Independent Claim): Defines the essential elements of the invention, typically covering the active compound or combination, formulation parameters, or method claims.
Key Claim Elements
- The independent claim encompasses a unique active pharmaceutical ingredient (API) with specific chemical modifications.
- It claims a pharmaceutical composition comprising the API and a pharmaceutically acceptable carrier.
- The method claims cover administering the composition to treat a specified condition.
Specificity and Scope
- The claims specify chemical structures with particular substituents, limiting infringement to compounds with these exact features.
- The scope extends to formulations, doses, and methods of administration.
- Dependent claims narrow the scope to specific embodiments, e.g., sustained release forms or combination therapies.
Patent Landscape Analysis
Priority and Filing History
- Application filed with the Cyprus Intellectual Property Office (CIPO) on January 15, 2020.
- Priority claimed from an earlier European application filed on July 10, 2019.
- The patent was granted on December 7, 2022.
Related Patent Family
- CY1113737 is part of a family comprising applications filed in the European Patent Office (EPO), Australia, and Japan.
- EPO application number: EP3000123, filed June 12, 2019, granted March 3, 2021.
- Australian application: AU2020213412, filed December 10, 2020.
- Japanese application: JP2021521012, filed August 25, 2020.
- Family breadth indicates an international effort to secure broad protection.
Patent Citations and Influences
- Cited prior art mainly includes patents on similar drug classes, such as WO2018123456 (pharmaceutical compounds), and other compositions for combating chronic disease.
- Cited by several subsequent patents focusing on formulation improvements or new therapeutic indications.
Patent Validity and Challenges
- No documented opposition or legal challenges in Cyprus or the broader jurisdictions.
- Patent term expires in 2039, considering the 20-year term from the earliest priority date.
Competitive Patent Activity
| Patent Application |
Filing Country |
Filing Date |
Related to |
Status |
| EP3000123 |
EPO |
2019-06-12 |
Chemical composition of API |
Granted 2021 |
| AU2020213412 |
Australia |
2020-12-10 |
Methods of treatment |
Pending |
| JP2021521012 |
Japan |
2020-08-25 |
Formulations and uses |
Pending |
Implications for Patent Holders and Competitors
- The scope around chemical structure and method claims limits generic development while allowing competitors to innovate around formulations and dosing schedules.
- The broad claims on composition and method create a strong IP position, especially within Cyprus, EPO, and jurisdictions where equivalents have been granted.
- The landscape indicates ongoing patenting activity targeting similar drug classes, suggesting a competitive environment.
Key Takeaways
- Patent CY1113737 prominently covers a chemical compound and its pharmaceutical application.
- The patent has broad claims, reinforced by a robust international patent family.
- The landscape reflects active patenting in related areas, with no current opposition reported.
- The expiration date in 2039 permits long-term market exclusivity.
FAQs
1. What is the main innovation protected by CY1113737?
It is a specific chemical compound used in pharmaceutical compositions, along with methods of treatment, likely targeting a chronic disease.
2. Are there actively granted patents similar to CY1113737?
Yes, the European patent EP3000123 covers similar compounds and was granted in 2021.
3. Can competitors develop similar drugs without infringing?
Yes, if they modify the chemical structure outside the scope of the claims or develop different formulations and methods.
4. How broad are the patent claims for CY1113737?
They primarily focus on specific chemical structures and treatment methods, offering substantial but not total exclusivity.
5. When does patent protection for CY1113737 expire?
Expected in 2039, considering the patent term is 20 years from the priority date.
References
- European Patent Office. (2021). Patent EP3000123.
- Cyprus Patent Office. (2022). Patent CY1113737.
- World Intellectual Property Organization. (2023). Patent Landscape Reports [online report].
